8-K
SANGAMO THERAPEUTICS, INC NASDAQ false 0001001233 0001001233 2026-10-14 2026-10-14
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 14, 2026

 

 

SANGAMO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-30171   68-0359556

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

ID Number)

 

501 Canal Blvd., Richmond, California 94804
(Address of principal executive offices) (Zip Code)

(510) 970-6000

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.01 par value per share   SGMO   Nasdaq Capital Market *

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

*

Following a determination by the Nasdaq Stock Market LLC (“Nasdaq”) to delist the common stock of Sangamo Therapeutics, Inc. (the “Company”), the Company’s common stock was suspended from trading on Nasdaq on May 5, 2026 and currently trades on the OTC Pink Limited Market under the symbol “SGMOQ”. On July 14, 2026, the Nasdaq Hearings Panel issued a written determination letter denying the Company’s request to continue its listing on Nasdaq. On October 7, 2026, Nasdaq filed a Form 25 with the Securities and Exchange Commission to delist and deregister the Company’s common stock under Section 12(b) of the Exchange Act, which will become effective October 17, 2026.

 

 
 


Item 7.01

Regulation FD Disclosure.

As previously announced, on June 23, 2026, Sangamo Therapeutics, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing a Chapter 11 case for the Company (the “Chapter 11 Case”). The case number is 26-10989 and the case is styled as In re Sangamo Therapeutics, Inc.

On October 14, 2026, the Company filed with the Bankruptcy Court its monthly operating report for the period beginning August 1, 2026 and ended August 31, 2026 (the “MOR”).

The information set forth in Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information required to be disclosed solely by Regulation FD. The MOR is attached hereto as Exhibit 99.1. The MOR and additional information regarding the Chapter 11 Case is available at https://www.veritaglobal.net/SangamoTherapeutics. The documents and other information on this website are not part of this Current Report on Form 8-K and shall not be incorporated by reference.

The information contained in this Item 7.01 and in Exhibit 99.1 is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

Cautionary Statement Regarding the MOR

The Company cautions investors and potential investors not to place undue reliance upon the information contained in the MOR, which was not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company. The MOR is limited in scope, covers a limited time period and has been prepared solely for the purpose of complying with the reporting requirements of the Bankruptcy Court. The MOR is not audited or reviewed by independent accountants, was not prepared in accordance with generally accepted accounting principles in the United States, is in a format prescribed by applicable bankruptcy laws or rules, and is subject to future adjustment and reconciliation. The MOR also contains information for periods shorter and otherwise different from those contained in the Company’s reports required to be filed pursuant to the Exchange Act. There can be no assurance that, from the perspective of an investor or potential investor in the Company’s securities, the MOR is complete. Results set forth in the MOR should not be viewed as indicative of future results.

Cautionary Language Regarding Trading in the Company’s Common Stock

The Company’s stockholders are cautioned that trading in the Company’s common stock during the pendency of the Chapter 11 Case is highly speculative and poses substantial risks. The Company’s common stock has been suspended from trading on the Nasdaq Capital Market (“Nasdaq”), and following the filing of a Form 25 by Nasdaq on October 7, 2026, will be delisted and deregistered under Section 12(b) of the Exchange Act effective October 17, 2026. The Company’s common stock is currently trading on the OTC Pink Limited Market under the symbol “SGMOQ,” and trading prices for the Company’s common stock may bear little or no relationship to the actual recovery, if any, by holders thereof in the Company’s Chapter 11 Case. Accordingly, the Company urges extreme caution with respect to existing and future investments in its common stock.

Cautionary Language Regarding Forward-Looking Statements

This Current Report on Form 8-K contains certain forward-looking statements that reflect, when made, the Company’s current views with respect to current events and financial performance. These forward-looking statements are within the meaning of Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding process and potential outcomes of the Company’s Chapter 11 Case and/or statements preceded by, followed by or that include the words “intends,” “expects,”


“estimates,” “plans,” or similar expressions. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, beliefs and expectations, there can be no assurance that its expectations will be achieved. Except as otherwise may be required by law, the Company undertakes no obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances, or changes in expectations after the date of this Current Report on Form 8-K.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

   Description of Document
99.1    Sangamo Therapeutics, Inc. Monthly Operating Report for the period ended August 31, 2026.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    SANGAMO THERAPEUTICS, INC.
Date: October 15, 2026     By:  

/s/ SCOTT B. WILLOUGHBY

      Scott B. Willoughby
      Chief Legal Officer and Corporate Secretary
EX-99.1

Exhibit 99.1

Case 26-10989-CTG Doc 513 Filed 10/14/26 Page 1 of 26

Docket #0513 Date Filed: 10/14/2026

UNITED STATES BANKRUPTCY COURT

      DISTRICT OF DELAWARE

 

                    

 

In Re. SANGAMO THERAPEUTICS, INC.   §   Case No. 26-10989
  §  
                        §  
Debtor(s)   §  
    ☐ Jointly Administered

 

Monthly Operating Report         Chapter 11
Reporting Period Ended: 08/31/2026     Petition Date: 06/23/2026      
Months Pending: 2        Industry Classification: LOGO
Reporting Method:    Accrual Basis LOGO    Cash Basis LOGO      
Debtor’s Full-Time Employees (current):    73      
Debtor’s Full-Time Employees (as of date of order for relief):    74      

Supporting Documentation (check all that are attached):

(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor)

 

☒

Statement of cash receipts and disbursements

☒

Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit

☒

Statement of operations (profit or loss statement)

 

☐

Accounts receivable aging

 

☐

Postpetition liabilities aging

 

☐

Statement of capital assets

 

☐

Schedule of payments to professionals

 

☒

Schedule of payments to insiders

☒

All bank statements and bank reconciliations for the reporting period

☒

Description of the assets sold or transferred and the terms of the sale or transfer

 

/s/ Nikunj Jain

    

Nikunj Jain

Signature of Responsible Party      Printed Name of Responsible Party

10/14/2026

    
Date     
    

501 Canal Blvd., Suite A100 Richmond, CA 94804

     Address

 

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. §1320.4(a)(2) applies.

 

LOGO

 

UST Form 11-MOR (12/01/2021)    1   


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 2 of 26

 

Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

Part 1: Cash Receipts and Disbursements

   Current Month      Cumulative  
a.    Cash balance beginning of month    $ 16,906,954     
     

 

 

    
b.    Total receipts (net of transfers between accounts)    $ 10,145,433      $ 38,707,494  
     

 

 

    

 

 

 
c.    Total disbursements (net of transfers between accounts)    $ 3,826,691      $ 20,338,902  
     

 

 

    

 

 

 
d.    Cash balance end of month (a+b-c)    $ 23,225,696     
     

 

 

    
e.    Disbursements made by third party for the benefit of the estate    $ 0      $ 0  
     

 

 

    

 

 

 
f.    Total disbursements for quarterly fee calculation (c+e)    $ 3,826,691      $ 20,338,902  
     

 

 

    

 

 

 

Part 2: Asset and Liability Status

(Not generally applicable to Individual Debtors. See Instructions.)

   Current Month         
a.    Accounts receivable (total net of allowance)    $ 90,355     
     

 

 

    
b.    Accounts receivable over 90 days outstanding (net of allowance)    $ 90,355     
     

 

 

    
c.    Inventory (Book  LOGO   Market  LOGO   Other  LOGO   (attach explanation))    $ 0     
     

 

 

    
d    Total current assets    $ 25,398,606     
     

 

 

    
e.    Total assets    $ 147,881,705     
     

 

 

    
f.    Postpetition payables (excluding taxes)    $ 28,270,062     
     

 

 

    
g.    Postpetition payables past due (excluding taxes)    $ 768,173     
     

 

 

    
h.    Postpetition taxes payable    $ 308,160     
     

 

 

    
i.    Postpetition taxes past due    $ 0     
     

 

 

    
j.    Total postpetition debt (f+h)    $ 28,578,222     
     

 

 

    
k.    Prepetition secured debt    $ 0     
     

 

 

    
l.    Prepetition priority debt    $ 32,543     
     

 

 

    
m.    Prepetition unsecured debt    $ 78,651,484     
     

 

 

    
n.    Total liabilities (debt) (j+k+l+m)    $ 107,262,249     
     

 

 

    
o.    Ending equity/net worth (e-n)    $ 40,619,456     
     

 

 

    

Part 3: Assets Sold or Transferred

   Current Month      Cumulative  
a.    Total cash sales price for assets sold/transferred outside the ordinary course of business    $ 2,300,000      $ 2,300,000  
     

 

 

    

 

 

 
b.    Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business    $ 0      $ 0  
     

 

 

    

 

 

 
c.    Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)    $ 2,300,000      $ 2,300,000  
     

 

 

    

 

 

 

Part 4: Income Statement (Statement of Operations)

(Not generally applicable to Individual Debtors. See Instructions.)

   Current Month      Cumulative  
a.    Gross income/sales (net of returns and allowances)    $ 430,190     
     

 

 

    
b.    Cost of goods sold (inclusive of depreciation, if applicable)    $ 0     
     

 

 

    
c.    Gross profit (a-b)    $ 430,190     
     

 

 

    
d.    Selling expenses    $ 0     
     

 

 

    
e.    General and administrative expenses    $ 3,679,482     
     

 

 

    
f.    Other expenses    $ 602,848     
     

 

 

    
g.    Depreciation and/or amortization (not included in 4b)    $ 137,645     
     

 

 

    
h.    Interest    $ 192,082     
     

 

 

    
i.    Taxes (local, state, and federal)    $ 0     
     

 

 

    
j.    Reorganization items    $ 9,979,799     
     

 

 

    
k.    Profit (loss)    $ -14,449,029      $ -29,369,386  
     

 

 

    

 

 

 

 

UST Form 11-MOR (12/01/2021)   2  


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 3 of 26

 

Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

Part 5: Professional Fees and Expenses

 

 

 

a. 

         Approved
Current Month
   Approved
Cumulative
   Paid Current
Month
     Paid
Cumulative
 
   Debtor’s professional fees & expenses (bankruptcy) Aggregate Total                $515,399        $515,399  
   Itemized Breakdown by Firm              
        Firm Name    Role
   i    Raymond James    Financial Professional                $175,000        $175,000  
   ii    Verita    Other                $340,399        $340,399  
   iii                                      
   iv                                      
   v                                      
   vi                                      
   vii                                      
   viii                                      
   ix                                      
   x                                      
   xi                                      
   xii                                      
   xiii                                      
   xiv                                      
   xv                                      
   xvi                                      
   xvii                                      
   xviii                                      
   xix                                      
   xx                                      
   xxi                                      
   xxii                                      
   xxiii                                      
   xxiv                                      
   xxv                                      
   xxvi                                      
   xxvii                                      
   xxviii                                      
   xxix                                      
   xxx                                      
   xxxi                                      
   xxxii                                      
   xxxiii                                      
   xxxiv                                      
   xxxv                                      
   xxxvi                                      

 

UST Form 11-MOR (12/01/2021)   3  


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 4 of 26

 

Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

                    
               
     xxxvii                              
   xxxviii                              
   xxxix                              
   xl                              
   xli                              
   xlii                              
   xliii                              
   xliv                              
   xlv                              
   xlvi                              
   xlvii                              
   xlviii                              
   xlix                              
   l                              
   li                              
   lii                              
   liii                              
   liv                              
   lv                              
   lvi                              
   lvii                              
   lviii                              
   lix                              
   lx                              
   lxi                              
   lxii                              
   lxiii                              
   lxiv                              
   lxv                              
   lxvi                              
   lxvii                              
   lxviii                              
   lxix                              
   lxx                              
   lxxi                              
   lxxii                              
   lxxiii                              
   lxxiv                              
   lxxv                              
   lxxvi                              
   lxxvii                              
   lxxviii                              

 

UST Form 11-MOR (12/01/2021)   4  


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 5 of 26

 

Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

     lxxix                              
   lxxx                              
   lxxxi                              
   lxxxii                              
   lxxxiii                              
   lxxxiv                              
   lxxxv                              
   lxxxvi                              
   lxxxvii                              
   lxxxviii                              
   lxxxix                              
   xc                              
   xci                              
   xcii                              
   xciii                              
   xciv                              
   xcv                              
   xcvi                              
   xcvii                              
   xcviii                              
   xcix                              
   c                              
   ci                              

 

 

 

b. 

         Approved
Current Month
   Approved
Cumulative
   Paid Current
Month
   Paid
Cumulative
   Debtor’s professional fees & expenses (nonbankruptcy) Aggregate Total                    
   Itemized Breakdown by Firm     
        Firm Name    Role
   i                              
   ii                              
   iii                              
   iv                              
   v                              
   vi                              
   vii                              
   viii                              
   ix                              
   x                              
   xi                              
   xii                              
   xiii                              
   xiv                              

 

UST Form 11-MOR (12/01/2021)   5  


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 6 of 26

 

Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

  

   xv                              
   xvi                              
   xvii                              
   xviii                              
   xix                              
   xx                              
   xxi                              
   xxii                              
   xxiii                              
   xxiv                              
   xxv                              
   xxvi                              
   xxvii                              
   xxviii                              
   xxix                              
   xxx                              
   xxxi                              
   xxxii                              
   xxxiii                              
   xxxiv                              
   xxxv                              
   xxxvi                              
   xxxvii                              
   xxxviii                              
   xxxix                              
   xl                              
   xli                              
   xlii                              
   xliii                              
   xliv                              
   xlv                              
   xlvi                              
   xlvii                              
   xlviii                              
   xlix                              
   l                              
   li                              
   lii                              
   liii                              
   liv                              
   lv                              
   lvi                              

 

UST Form 11-MOR (12/01/2021)   6  


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 7 of 26

 

Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

  

   lvii                              
   lviii                              
   lix                              
   lx                              
   lxi                              
   lxii                              
   lxiii                              
   lxiv                              
   lxv                              
   lxvi                              
   lxvii                              
   lxviii                              
   lxix                              
   lxx                              
   lxxi                              
   lxxii                              
   lxxiii                              
   lxxiv                              
   lxxv                              
   lxxvi                              
   lxxvii                              
   lxxviii                              
   lxxix                              
   lxxx                              
   lxxxi                              
   lxxxii                              
   lxxxiii                              
   lxxxiv                              
   lxxxv                              
   lxxxvi                              
   lxxxvii                              
   lxxxviii                              
   lxxxix                              
   xc                              
   xci                              
   xcii                              
   xciii                              
   xciv                              
   xcv                              
   xcvi                              
   xcvii                              
   xcviii                              
   xcix                              
               
     c                              
         

c.   All professional fees and expenses (debtor & committees)

   $  0    $  0    $515,399    $515,399

 

UST Form 11-MOR (12/01/2021)   7  


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 8 of 26

 

Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

Part 6: Postpetition Taxes

   Current Month      Cumulative  

a.   Postpetition income taxes accrued (local, state, and federal)

   $ 0      $ 0  
  

 

 

    

 

 

 

b.  Postpetition income taxes paid (local, state, and federal)

   $ 0      $ 0  
  

 

 

    

 

 

 

c.   Postpetition employer payroll taxes accrued

   $ 211,413      $ 493,588  
  

 

 

    

 

 

 

d.  Postpetition employer payroll taxes paid

   $ 455,499      $ 877,333  
  

 

 

    

 

 

 

e.   Postpetition property taxes paid

   $ 361,948      $ 361,948  
  

 

 

    

 

 

 

f.   Postpetition other taxes accrued (local, state, and federal)

   $ 96,747      $ 154,151  
  

 

 

    

 

 

 

g.  Postpetition other taxes paid (local, state, and federal)

   $ 0      $ 0  
  

 

 

    

 

 

 

 

Part 7: Questionnaire - During this reporting period:

                       

a.   Were any payments made on prepetition debt? (if yes, see Instructions)

   Yes    LOGO    No    LOGO  

b.  Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions)

   Yes    LOGO    No    LOGO  

c.   Were any payments made to or on behalf of insiders?

   Yes    LOGO    No    LOGO  

d.  Are you current on postpetition tax return filings?

   Yes    LOGO    No    LOGO  

e.   Are you current on postpetition estimated tax payments?

   Yes    LOGO    No    LOGO  

f.   Were all trust fund taxes remitted on a current basis?

   Yes    LOGO    No    LOGO  

g.  Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions)

   Yes    LOGO    No    LOGO  

h.  Were all payments made to or on behalf of professionals approved by the court?

   Yes    LOGO    No    LOGO   N/A LOGO

i.   Do you have:   Worker’s compensation insurance?

   Yes    LOGO    No    LOGO  

  If yes, are your premiums current?

   Yes    LOGO    No    LOGO   N/A LOGO  (if no, see Instructions)

  Casualty/property insurance?

   Yes    LOGO    No    LOGO  

  If yes, are your premiums current?

   Yes    LOGO    No    LOGO   N/A LOGO   (if no, see Instructions)

  General liability insurance?

   Yes    LOGO    No    LOGO  

  If yes, are your premiums current?

   Yes    LOGO    No    LOGO   N/A LOGO  (if no, see Instructions)

j.   Has a plan of reorganization been filed with the court?

   Yes    LOGO    No    LOGO  

k.  Has a disclosure statement been filed with the court?

   Yes    LOGO    No    LOGO  

l.   Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930?

   Yes    LOGO    No    LOGO  

 

UST Form 11-MOR (12/01/2021)   8  


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 9 of 26

 

Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

Part 8: Individual Chapter 11 Debtors (Only)

                   

a.   Gross income (receipts) from salary and wages

            $   0
           

 

b.  Gross income (receipts) from self-employment

            $   0
           

 

c.   Gross income from all other sources

            $   0
           

 

d.  Total income in the reporting period (a+b+c)

            $   0
           

 

e.   Payroll deductions

            $   0
           

 

f.   Self-employment related expenses

            $   0
           

 

g.  Living expenses

            $   0
           

 

h.  All other expenses

            $   0
           

 

i.   Total expenses in the reporting period (e+f+g+h)

            $   0
           

 

j.   Difference between total income and total expenses (d-i)

            $   0
           

 

k.  List the total amount of all postpetition debts that are past due

            $   0
           

 

l.   Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)?

   Yes  LOGO    No  LOGO      

m.   If yes, have you made all Domestic Support Obligation payments?

   Yes  LOGO    No  LOGO    N/A  LOGO   

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor’s progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee’s or examiner’s duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee’s systems of records notice, UST-001, “Bankruptcy Case Files and Associated Records.” See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/ eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.

 

/s/ Nikunj Jain

         

Nikunj Jain

Signature of Responsible Party       Printed Name of Responsible Party

Interim Chief Financial Officer

     

10/14/2026

Title       Date

 

UST Form 11-MOR (12/01/2021)   9  


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 10 of 26

 

Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

LOGO

PageOnePartOne PageOnePartTwo PageTwoPartOne PageTwoPartTwo

 

UST Form 11-MOR (12/01/2021)   10  


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 11 of 26

 

Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

LOGO

Bankruptcy1to50 Bankruptcy51to100 NonBankruptcy1to50 NonBankruptcy51to100

 

UST Form 11-MOR (12/01/2021)   11  


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 12 of 26

 

Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

LOGO

 

UST Form 11-MOR (12/01/2021)   12  


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 13 of 26

 

IN THE UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT DELAWARE

 

 
   )   
In re:    )    Chapter 11
   )   
SANGAMO THERAPEUTICS, INC.     )    Case No. 26-10989 (CTG)
   )   

Debtor.1

   )   

 

   )   

GLOBAL NOTES AND STATEMENT OF LIMITATIONS, METHODOLOGY, AND DISCLAIMERS REGARDING THE DEBTOR’S MONTHLY OPERATING REPORT

 

On June 23, 2026 (the “Petition Date”), Sangamo Therapeutics, Inc. (the “Debtor”) commenced the above-captioned chapter 11 case by filing a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) with the United States Bankruptcy Court for the District of Delaware (the “Court”). The Debtor is authorized to operate its business as a debtor-in-possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code.

General Methodology

The Debtor is filing its monthly operating report (the “MOR”) for the period from August 1, 2026 through August 31, 2026 (the “Reporting Period”) for purposes of complying with the monthly reporting requirements applicable in the Debtor’s chapter 11 case. The MOR is unaudited and has not been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and does not include all of the information and footnotes required by U.S. GAAP. The MOR is not intended to reconcile to any financial statements otherwise prepared or distributed by the Debtor. The MOR should not be relied upon by any persons for information relating to current or future financial condition, events, or performance of the Debtor or its affiliates, as the results of operations contained herein are not necessarily indicative of results which may be expected from any other period or for the full year and may not necessarily reflect the results of operations, financial position, and schedule of receipts and disbursements in the future.

Basis for Presentation

In preparing the MOR, the Debtor relied on financial information from its books and records at the time of such preparation. The financial information contained in the MOR is derived from the Debtor’s books and records without, among other things, all adjustments or reclassification that may be necessary or typical to accord with U.S. GAAP.

 
1 

The Debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The Debtor’s mailing address is 7000 Marina Blvd, Brisbane, CA 94005.


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 14 of 26

 

This information has not been subjected to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtor believes that the financial information presented in the MOR could be subject to change, including material change.

Although the Debtor made efforts to ensure the accuracy and completeness of the MOR, given the complexity of the Debtor’s business, inadvertent errors or omissions may occur. Accordingly, the Debtor hereby reserves all rights to dispute the nature, validity, status, enforceability, or executory nature of any claim amount, agreement, representation, or other statement set forth in the MOR. Further, the Debtor reserves the right to amend or supplement the MOR, if necessary, but shall be under no obligation to do so.

Moreover, given, among other things, the uncertainty surrounding the valuation and ownership of certain assets and the valuation and nature of certain liabilities, to the extent the Debtor shows more assets than liabilities, it is not an admission that the Debtor was solvent as of the Petition Date or at any time prior to the Petition Date. Likewise, to the extent the Debtor shows more liabilities than assets, it is not an admission that the Debtor was insolvent at the Petition Date or any time prior to the Petition Date.

For the reasons discussed above, there can be no assurance that the financial information presented in the MOR is complete, and readers are strongly cautioned not to place undue reliance on the MOR.

Each signatory to the MOR has necessarily relied upon the efforts, statements, advice, and representations of personnel of the Debtor and the Debtor’s advisors and professionals. Each signatory has not (and could not have) personally verified the accuracy of each such statement, representation, and answer contained in the MOR.

Reporting Period

Unless otherwise noted herein, the MOR generally reflects the Debtor’s books and records for the applicable Reporting Period. Unless otherwise noted herein, no adjustments have been made for activity occurring after the close of the Reporting Period.

Accuracy

The financial information disclosed in the MOR was not prepared in accordance with federal or state securities laws or other applicable non-bankruptcy law or in lieu of complying with any periodic reporting requirements thereunder. Persons and entities trading in or otherwise purchasing, selling, or transferring the claims against or equity interests in the Debtor should evaluate the financial information in light of the purposes for which it was prepared. The Debtor and its advisors are not liable for and undertake no responsibility to indicate variations from securities laws in the MOR or for any evaluations of the Debtor, including of their financial condition, based on this financial information or any other information.


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 15 of 26

 

Debtor in Possession Financing

On June 25, 2026, the Court entered the Interim Order (A) Authorizing the Debtor to Obtain Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief [Docket No. 63] (the “Initial Interim DIP Order”) authorizing the Debtor to enter into a senior secured superpriority debtor-in-possession term loan facility (the “Initial DIP Facility”). Prior to the Reporting Period, the Debtor drew $10,500,000 under the Initial DIP Facility. Please refer to the motion [Docket No. 10] seeking entry of the Initial Interim DIP Order for additional information regarding the Initial DIP Facility.

On July 23, 2026, the Court entered the Interim Order (A) Authorizing the Debtor to Obtain Replacement Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief [Docket No. 176] (the “Replacement Interim DIP Order”), which, among other things, authorized the Debtor to enter into a senior secured superpriority debtor-in possession term loan facility (the “Replacement DIP Facility”) with Future Solution Investments LLC (“FSI”), as lender, to replace the Initial DIP Facility. Prior to the Reporting Period, the Debtor incurred $18 million in DIP Obligations (as defined in the Replacement DIP Order) under the Replacement DIP Facility, $11,432,958 of which was paid by the Debtor or on the Debtor’s behalf to satisfy all outstanding obligations arising under the Initial DIP Facility, including all fees. Please refer to the motion [Docket No. 161] (the “Replacement DIP Motion”) seeking entry of the Replacement Interim DIP Order for additional information regarding the Replacement DIP Facility.

On August 20, 2026, the Court entered an order [Docket No. 360] (the “Replacement Final DIP Order,” and together with the Initial Interim DIP Order and the Replacement Interim DIP Order, the “DIP Orders”) granting the relief requested in the Replacement DIP Motion on a final basis. The Final Replacement DIP Order authorized the Debtor to borrow up to $35 million under the Replacement DIP Facility ($17 million more than was authorized by the Replacement Interim DIP Order). During the Reporting Period, (i) the Debtor drew $7 million in additional DIP Obligations under the Replacement Final DIP Order, and (ii) FSI credit bid $250,000 of DIP Obligations in connection with the FSI Equipment Sale (as defined below).

Payment of Prepetition Claims Pursuant to First Day Orders

Pursuant to certain interim orders of the Court entered on or about June 24, 2026 and final orders of the Court entered on or about July 21, 2026 (the “First Day Orders”), the Debtor is authorized (but not directed) to pay, among other things, certain prepetition claims of employees and taxing authorities. Accordingly, these liabilities may have been or may be satisfied in accordance with such First Day Orders. To the extent any payments were made on account of prepetition claims following the Petition Date pursuant to the authority granted to the Debtor under the First Day Orders, such payments have been included in the MOR (subject to the notes and statements and limitations provided herein).

Reservation of Rights

The Debtor reserves all rights to amend or supplement the MOR in all respects, as may be necessary or appropriate. Nothing contained in the MOR shall constitute a waiver of any of the Debtor’s rights or an admission with respect to any claim against the Debtor or otherwise in connection with this chapter 11 case.


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 16 of 26

 

Specific MOR Disclosures

Part 1: Cash Receipts and Disbursements

Pursuant to the DIP Orders, fees and expenses of estate professionals were placed into the Professional Fees Account (as defined in the DIP Orders) maintained by the Debtor. The transfer of such funds to the Professional Fee Account were treated as a transfer between Debtor accounts, and, therefore, were not treated as a distribution in Part 1(c). Professional fees will be treated as a disbursement in the reporting period in which they are paid to the applicable professionals.

Similarly, pursuant to the interim and final orders approving, among other things, the Debtor’s proposed form of adequate assurance of payment to utility companies [Docket Nos. 56 & 142] (the “Utilities Orders”), the Debtor deposited funds into the Utility Deposit Account (as defined in the Utilities Orders) prior to the Reporting Period. The Utility Deposit Account is a segregated account maintained by the Debtor. Accordingly, the funds in such account will be treated as disbursements only if they are ultimately paid to a third party.

Notes to Part 2: Asset and Liability Status

Unless otherwise noted, all asset and liability information included in the MOR reflects net book value, which may differ from current market value. As set forth above, this information has not been subjected to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtor believes that the financial information presented in the MOR could be subject to change, including material change. Asset and liability information includes intercompany claims and other assets and liabilities which may not be settled in cash.

The Debtor continues to pay postpetition invoices on account of postpetition goods provided and services rendered in the ordinary course of business.

Given the Petition Date did not occur at month end, certain prepetition and postpetition liability balances are estimated. The Debtor has sought to assign liabilities to the prepetition and postpetition periods based on the information available as of and at the time the MOR was prepared. As additional information becomes available, the allocation of liabilities between prepetition and postpetition periods may change. The Debtor reserves the right to amend the balances as it deems appropriate and any such amendments will be reflected in future MORs.

The amounts listed as “Prepetition Secured Debt,” “Prepetition Priority Debt” and “Prepetition Unsecured Debt” are preliminary and are subject to ongoing review and reconciliation by the Debtor. All amounts and classifications are subject to material adjustments.

Regarding Part 2c, the Debtor does not hold inventory; therefore, no inventory valuation method is applicable.


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 17 of 26

 

Note to Part 3: Assets Sold or Transferred

On August 20, 2026, the Court entered: (i) an order [Docket No. 356] approving the sale (the “Surplus Equipment Sale”) of certain equipment and office furniture to Surplus Solutions, LLC for $2,300,000 plus certain other consideration, and (ii) an order [Docket No. 358] approving the sale (the “FSI Equipment Sale,” and together with the Surplus Equipment Sale, the “Equipment Sales”) of certain lab equipment to FSI for an offset of $250,000 against the DIP Obligations (as defined in the Replacement Final DIP Order) plus certain other consideration. Both equipment sales closed on or about August 20, 2026.

Notes to Part 5: Professional Fees and Expenses

All payments to professionals were authorized by the Court’s orders approving the retention of various professionals in this Chapter 11 Case. For the Reporting Period, such amounts represent: (i) fees paid to Kurtzman Carson Consultants, LLC dba Verita Global for services performed and expenses incurred in connection with its retention as claims and noticing agent (see Docket No. 55), and (ii) a monthly fee payable to Raymond James & Associates, Inc., which is payable each month without a prior fee application (see Docket No. 276).

Notes to Part 6: Postpetition Taxes

Regarding Part 6c and 6d, postpetition employer payroll taxes accrued and paid include both the employer and employee portions of payroll taxes.

Notes to Part 7: Questionnaire

Please see attached attestations regarding post-petition borrowing, payments on prepetition debt, and payments to insiders.


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 18 of 26

 

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

 

Sangamo Therapeutics, Inc.

Schedule of Post-Petition Borrowing Activity

  

Case No: 26-10989

Reporting Period: August 1, 2026 – August 31, 2026

 

 

The Debtor hereby submits this attestation regarding postpetition borrowing during the period of August 1, 2026 through August 31, 2026.

Pursuant to the Final Order (A) Authorizing the Debtor to Obtain Replacement Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief [Docket No. 360] (the “Replacement Final DIP Order”) during the reporting period: (i) the Debtor incurred $7 million in DIP Obligations under the Replacement DIP Facility (each as defined in the Replacement Final DIP Order), and (ii) FSI credit bid $250,000 of DIP Obligations in connection with the FSI Equipment Sale.

 

/s/ Nikunj Jain

    

October 14, 2026

Signature of Authorized Individual          Date

Nikunj Jain

    

Interim Chief Financial Officer

Printed Name of Authorized Individual      Title of Authorized Individual


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 19 of 26

 

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

 

Sangamo Therapeutics, Inc.

Schedule of Payments on Prepetition Debt

  

Case No: 26-10989

Reporting Period: August 1, 2026 – August 31, 2026

 

 

All payments made by the Debtor during the Reporting Period (and included in the disbursements reported in this MOR) were authorized under various final orders granted by the Court, which authorized the Debtor’s various motions that were filed following the commencement of the chapter 11 case.

 

/s/ Nikunj Jain

    

October 14, 2026

Signature of Authorized Individual          Date

Nikunj Jain

    

Interim Chief Financial Officer

Printed Name of Authorized Individual      Title of Authorized Individual


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 20 of 26

 

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

 

Sangamo Therapeutics, Inc.

Schedule of Payments to Insiders

  

Case No: 26-10989

Reporting Period: August 1, 2026 – August 31, 2026

 

 

The Debtor hereby submits this attestation regarding payments to insiders during the period of August 1, 2026 through August 31, 2026.

With respect to insiders, all cash payments made were on account of ordinary course salaries and authorized travel and expense reimbursements.

On July 31, 2026, the Court entered an order [Docket No. 216], among other things, authorizing the Debtor to implement a key employee retention program and a key employee incentive program (the “KEIP/KERP Programs”). No payments were made under the KEIP/KERP Programs to insiders or otherwise during the Reporting Period.

As set forth in the Debtor’s motion seeking authority to pay prepetition employee obligations [Docket No. 9], the Debtor maintained certain equity-based compensation programs prior to the Petition Date. Pursuant to such programs, certain employees, including certain executives that may be insiders, were awarded restricted stock units (the “RSUs”) prior to the Petition Date. During the Reporting Period, 213,628 RSUs awarded to 74 individuals prior to the Petition Date vested. For the avoidance of doubt, the Debtor stopped awarding RSUs prior to the Petition Date and no RSUs or any other form of equity-based compensation have been awarded since the Petition Date.

No other non-cash transfers were made during this reporting period.

 

/s/ Nikunj Jain

    

October 14, 2026

Signature of Authorized Individual          Date

Nikunj Jain

    

Interim Chief Financial Officer

Printed Name of Authorized Individual      Title of Authorized Individual


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 21 of 26

 

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

 

Sangamo Therapeutics, Inc.

All bank statements and bank reconciliations for the reporting period

  

Case No: 26-10989

Reporting Period: August 1, 2026 – August 31, 2026

 

 

The Debtor hereby submits this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, bank reconciliations, and journal entries.

The Debtor’s standard practice is to ensure that bank reconciliations are completed as part of the month end close each reporting period. I attest that each of the Debtor’s bank accounts has been reconciled in accordance with its standard practices.

 

/s/ Nikunj Jain

    

October 14, 2026

Signature of Authorized Individual          Date

Nikunj Jain

    

Interim Chief Financial Officer

Printed Name of Authorized Individual      Title of Authorized Individual


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 22 of 26

 

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

 

Sangamo Therapeutics, Inc.

Assets Sold or Transferred

  

Case No: 26-10989

Reporting Period: August 1, 2026 – August 31, 2026

 

 

The Debtor hereby submits this attestation regarding assets sold or transferred during the period of August 1, 2026 through August 31, 2026.

On August 20, 2026, the Court entered: (i) an order [Docket No. 356] approving the sale (the “Surplus Equipment Sale”) of certain equipment and office furniture to Surplus Solutions, LLC for $2,300,000 plus certain other consideration, and (ii) an order [Docket No. 358] approving the sale (the “FSI Equipment Sale,” and together with the Surplus Equipment Sales, the “Equipment Sales”) of certain lab equipment to FSI for an offset of $250,000 against the DIP Obligations (as defined in the Replacement Final DIP Order) plus certain other consideration. Both equipment sales closed on or about August 20, 2026.

 

/s/ Nikunj Jain

    

October 14, 2026

Signature of Authorized Individual          Date

Nikunj Jain

    

Interim Chief Financial Officer

Printed Name of Authorized Individual      Title of Authorized Individual


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 23 of 26

 

Sangamo Therapeutics Inc.

 

MOR #3 - Statement of cash receipts and disbursements

$ in 000s

 

     07/01/2026 -
07/31/2026
     08/01/2026 -
08/31/2026
 

Receipts

     

Receipts

   $ 59      $ 3,145  

DIP Draw

   $ 18,000      $ 7,000  
  

 

 

    

 

 

 

Total Receipts

   $ 18,059      $ 10,145  

Operational Disbursements

     

Payroll & Benefits

   $ 1,747      $ 1,693  

Rent & Facilities

     1,348        319  

Program Costs

     319        226  

International Operations

     416        240  

Other Operating Disbursements

     271        579  
  

 

 

    

 

 

 

Total Operational Disbursements

   $ 4,101      $ 3,057  

Restructuring Disbursements

     

Professional Fees

     —       $ 515  

US Trustee Fees

     —         4  

DIP Interest & Fees

     933        250  

DIP Repayments

     10,500        —   
  

 

 

    

 

 

 

Total Restructuring Disbursements

   $ 11,433      $ 769  

Net Cash Flow

   $ 2,525      $ 6,319  

Cash, cash equivalents, and restricted cash, beginning of period

   $ 14,382      $ 16,907  
  

 

 

    

 

 

 

Cash, cash equivalents, and restricted cash, end of period

   $ 16,907      $ 23,226  
  

 

 

    

 

 

 

 

1 of 4


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 24 of 26

 

Sangamo Therapeutics Inc.

 

MOR #3 - Balance sheet

$ in 000s

 

     As of  
     07/31/2026     08/31/2026  

Assets

    

Cash, Cash Equivalents and Restricted Cash

     $    16,910       $    23,197  

Accounts Receivables

     500       90  

Other Current Assets

     2,977       2,111  
  

 

 

   

 

 

 

Total Current Assets

     $    20,387       $    25,399  

Property, Plant & Equipment (Net)

     $     9,430       $2  

Right of Use Assets3

     2,694       —   

Other Non-Current Assets

     779       613  

Investments in Subsidiaries

     115,762       115,762  

I/C Receivables - Non-Current

     6,067       6,106  
  

 

 

   

 

 

 

Total Non-Current Assets

     $   134,731       $   122,483  
  

 

 

   

 

 

 

Total Assets

     $   155,118       $   147,882  
  

 

 

   

 

 

 

Liabilities and Stockholders’ Equity

    

A/P and Accrued Liabilities

     $    36,735       $    44,182  

Compensation and Benefits Liabilities

     17,304       17,397  

DIP Loan Payables2

     18,000       24,942  

Other Current Liabilities1

     8,713       9,723  

I/C Payables - Current

     42,687       42,903  

Other Non-Current Liabilities1

     23,240       14,754  

I/C Payables - Non-Current

     703       708  
  

 

 

   

 

 

 

Total Liabilities

     $   147,383       $   154,609  

Stock

     $ 1,643,342       $ 1,643,328  

Retained Earnings

     (1,564,836 )      (1,564,836 ) 

Other Equity

     (30 )      (30 ) 

Net Income

     (70,741 )      (85,190 ) 

Total Stockholders’ Equity

     $     7,735       ($     6,727 ) 
  

 

 

   

 

 

 

Total Liabilities and Stockholders’ Equity

     $   155,118       $   147,882  
  

 

 

   

 

 

 

Notes:

 

1.

Includes:

 

  a.

Deferred Revenues

 

  b.

Lease Liabilities; the Richmond lease is presented as a one-year liability, estimated for lease rejection purposes

 

2.

Includes accrued August DIP interest of $192K (paid 9/2); net of FSI’s $250K lab equipment credit bid

3.

Fully written off in August in connection with the wind-down of Richmond facility

 

2 of 4


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 25 of 26

 

Sangamo Therapeutics Inc.

 

MOR #3 - Statement of operations (profit or loss statement)

$ in 000s

 

     07/01/2026 -
07/31/2026
    08/01/2026 -
08/31/2026
 

Total Revenue

     $    720       $    430  

COGS

     —        —   
  

 

 

   

 

 

 

Gross Profit

     $    720       $    430  

Personnel & Staffing Costs1

     $  1,931       $  1,693  

R&D Expenses2

     3,184       473  

Selling Expenses

     —        —   

General and Administrative Expenses4

     863       1,037  

Facilities & OH Expenses1

     972       950  

I/C Expenses2

     28       127  

Other Expenses2

     19       3  

Interest Expense

     105       192  

Restructuring Expenses3

     4,244       9,980  

Depreciation and/or amortization

     216       138  
  

 

 

   

 

 

 

Total Operating Expenses

     $ 11,562       $ 14,592  

Unrealized FX (Gain)/Loss

     $    336       $    292  

Non-Operating (Income)/Expense

     (12 )      (5 ) 
  

 

 

   

 

 

 

Total Non-Operating (Income)/Expense

     $    323       $    287  
  

 

 

   

 

 

 

Net Profit/(Loss) for the Period

     ($ 11,165 )      ($ 14,449 ) 
  

 

 

   

 

 

 

Notes:

 

1.

Considered under “General and Administrative Expenses” for MOR

2.

Considered under “Other Expenses” for MOR

3.

Includes professional fees and asset write-offs/disposals, net of lease rejection gains

4.

Includes D&O insurance expense for prior months not previously recognized, recorded in August

 

3 of 4


Case 26-10989-CTG  Doc 513  Filed 10/14/26  Page 26 of 26

 

Sangamo Therapeutics Inc.

 

MOR #3 - Detailed explanations

Part 2 - Question C - Inventory

Sangamo does not hold inventory; therefore, no inventory valuation method is applicable

Part 7 - Question G - Was there any postpetition borrowing, other than trade credit?

 

Detail

   Date    Payee/Lender Name    Amount  

DIP draw

   8/21/2026    Future Solution Investments LLC    $ 7,000,000  

 

4 of 4